The processor HTA has designed should enable the CSS to interpret the sub-sonic and infrasonic sound waves it intakes, and allow for the results to be displayed on a monitor in real time.

Speaking on behalf of CVR's executive leadership, CEO Peter Bakema expresses great confidence in HTA's unique ability to design state-of-the-art products that impact the world. "We feel incredibly fortunate for our partnership with HTA, through which we've enhanced our own technological and organizational backbone significantly."

Mr. Thomas Heiser, HTA Vice President and General Manager of HTA's Systems Products Division, states, "We work on medical projects with the hope that they may become the tools that change a particular field.

“To be able to bring this sort of technology into doctors' offices, at a potentially high volume that is rare for medical devices, is what makes this opportunity so exciting. We're looking forward to working with CVR, and realizing that potential as they scale out to meet what we expect will be great demand for the CSS."

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the Joint Venture).

The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis.

 CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.